iShares Global Healthcare ETF (IXJ)
| Assets | $4.15B |
| Expense Ratio | 0.40% |
| PE Ratio | 23.30 |
| Shares Out | 43.60M |
| Dividend (ttm) | $1.36 |
| Dividend Yield | 1.34% |
| Ex-Dividend Date | Dec 16, 2025 |
| Payout Ratio | 31.46% |
| 1-Year Return | +9.78% |
| Volume | 129,510 |
| Open | 100.26 |
| Previous Close | 100.31 |
| Day's Range | 100.23 - 101.78 |
| 52-Week Low | 80.68 |
| 52-Week High | 101.78 |
| Beta | 0.61 |
| Holdings | 129 |
| Inception Date | Nov 13, 2001 |
About IXJ
Fund Home PageThe iShares Global Healthcare ETF (IXJ) is an exchange-traded fund that is based on the S&P Global 1200 / Health Care index, a market-cap-weighted index of global health care companies. IXJ was launched on Nov 13, 2001 and is issued by BlackRock.
Top 10 Holdings
45.58% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.95% |
| Johnson & Johnson | JNJ | 7.19% |
| AbbVie Inc. | ABBV | 4.87% |
| Roche Holding AG | ROG | 4.05% |
| AstraZeneca PLC | AZN | 3.88% |
| Novartis AG | NOVN | 3.86% |
| Merck & Co., Inc. | MRK | 3.63% |
| UnitedHealth Group Incorporated | UNH | 3.18% |
| Amgen Inc. | AMGN | 2.50% |
| Abbott Laboratories | ABT | 2.47% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $0.59765 | Dec 19, 2025 |
| Jun 16, 2025 | $0.7628 | Jun 20, 2025 |
| Dec 17, 2024 | $0.61725 | Dec 20, 2024 |
| Jun 11, 2024 | $0.67232 | Jun 17, 2024 |
| Dec 20, 2023 | $0.55622 | Dec 27, 2023 |
| Jun 7, 2023 | $0.6436 | Jun 13, 2023 |
News
IXJ: Healthcare Sector Dashboard For February
While the broad market is overpriced, value still exists in the healthcare sector, especially in healthcare providers and healthcare equipment. iShares Global Healthcare ETF offers global healthcare e...
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
IXJ: Healthcare Sector Dashboard For October
Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. iShares Global Healthcare ETF (IXJ):...
On IXJ, A Contradiction Has Emerged That Is Too Big To Be Ignored
Tough moment for healthcare: low momentum, high volatility, and downgraded EPS. It is evident when looking at the IXJ ETF, focused on global healthcare: 70% US, 30% international. But relative valuati...
IXJ: A Bet On Global Healthcare Recovery
IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs for a more balanced risk/reward profile. The fund's heavy allocation to pharmaceutica...
IXJ: Healthcare Sector Dashboard For May
This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Healthcare providers and pharmaceuticals/biotechnology are the most compelling subsectors...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
IXJ: Healthcare Sector Dashboard For November
The healthcare sector is overvalued by 18% relative to 11-year averages, with pharmaceuticals/biotechnology and healthcare equipment most overpriced. IXJ offers global healthcare exposure with lower c...
IXJ: Healthcare Sector Dashboard For August
Monthly article series showing healthcare industry metrics. The healthcare sector is overvalued by about 18% relative to 11-year averages. The most overvalued subsector is pharmaceuticals and biotechn...
IXJ: Growth Expected To Be Very Strong In The Next Few Years
iShares Global Healthcare ETF has underperformed the S&P 500 index in the past few years. IXJ has lower volatility and downside risk compared to the broader market. The healthcare sector is expected t...
IXJ: Healthcare Sector Dashboard For March
The healthcare sector is overvalued by about 13% relative to 11-year averages, but overvaluation varies a lot across subsectors. Healthcare equipment has the worst value and quality scores. iShares Gl...
IXJ: Healthcare Dashboard For December
The healthcare sector valuation is close to 11-year averages. Pharmaceuticals/biotechnology and life science tools are close to the historical baseline, while healthcare equipment is the less attracti...
IXJ: Healthcare Dashboard For September
The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attra...
Biden calls IRA ‘one of the most significant laws' ever as he promotes climate investments
President Joe Biden on Wednesday marked the first anniversary of his Inflation Reduction Act, a massive package of climate and healthcare initiatives that is part of his broader “Bidenomics” program.
IXJ: Potential To Generate Steady Price Growth Over The Long Run
As the populations of most wealthy countries continue to age, the healthcare sector is going to benefit irrespective of economic conditions. Investors are continuing to opt for stocks from safer secto...
IXJ: Healthcare Dashboard For April
Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one.
IXJ: Long-Term Buy On Global Healthcare Tailwinds
iShares Global Healthcare ETF has beaten the S&P 500 over the past 5 years while having less volatility. The IXJ ETF is full of high-quality companies and is globally diversified, lowering the risk of...
IXJ Has A Shot At Earnings Growth But Is Still Too Expensive
Earnings growth can happen in this ETF, which is supported by some insurance economics, but also simple demographics and resilient healthcare demand. Earnings growth is hard to come by in current mark...
IXJ Is Resilient But No Strong Angle
IXJ gives you very broad-based healthcare exposure. But the bet isn't narrow enough to provide a strong angle or particularly good value.
IXJ: Healthcare Dashboard For May
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued.
IXJ: A Healthcare ETF For Long Term Hold
After poor performance during 2015 to 2018, IXJ reshuffled its portfolio. Price return in the past 3 years is good and even better in the longer period.